



**Introduction to Session:**  
**Combined Diphtheria and Tetanus Toxoids and Acellular  
Pertussis, Inactivated Poliovirus, *Haemophilus influenzae*  
Type b Conjugate, and Hepatitis B vaccine (Vaxelis)**

**Jamie Loehr, MD**  
**Chair, ACIP Hib/Meningococcal Vaccines Work Group**

June 26, 2024

# ACIP Meningococcal/Hib Vaccines Work Group

- ACIP Members on the WG
  - Jamie Loehr (Chair)
  - Wilbur Chen
  
- Ex Officio WG Members
  - Margaret Bash (FDA)
  - Matthew Clark (IHS)
  - Xin-Xing Gu (NIH)
  
- WG Liaisons and Consultants
  - Amra Resic (AAFP)
  - Mary Healy (AAP)
  - Barb Fluty (ACHA)
  - Karyn Lyons (AIM)
  - Paul Cieslak (CSTE)
  - Kathy Hsu (IDSA)
  - Pamela Doyon-Plourde (NACI)
  - Jeff Goad (NFID)
  - Jessica Cataldi (PIDS)
  - Amy Middleman (SAHM)
  - Kathy Poehling (Wake Forest)
  - Lynn Bahta (Minnesota Department of Health)
  - David Stephens (Emory)
  
- GRADE/EtR Support
  - Doug Campos-Outcalt (Arizona)
  - Rebecca Morgan (Case Western Reserve)
  
- CDC Contributors
  - Jennifer Collins (DBD/NCIRD)
  - Sarah Schillie (DBD/NCIRD)
  - Lucy McNamara (DBD/NCIRD)
  - LeAnne Fox (DBD/NCIRD)
  - Susan Hariri (DBD/NCIRD)
  - Amy Rubis (DBD/NCIRD)
  - Gabrielle Cooper (DBD/NCIRD)
  - Noele Nelson (DBD/NCIRD)
  - Alison Albert (DBD/NCIRD)
  - Shelby Miller (DBD/NCIRD)
  - Marc Fischer (DIDRI/NCEZID)
  - Xiaoyu Dong (ISD/NCIRD)
  - Andrew Leidner (ISD/NCIRD)
  - Ismael Ortega-Sanchez (CORVD/NCIRD)
  - Jonathan Duffy (DHQP/NCEZID)
  - Pedro Moro (DHQP/NCEZID)
  - Tanya Myers (DHQP/NCEZID)
  - Liz Velazquez (ISD/NCIRD)
  - Jessica MacNeil (ACIP Secretariat)
  - Hannah Rosenblum (ACIP Secretariat)
  - Melinda Wharton (ACIP Secretariat)

# Background

- PRP-OMP (PedvaxHIB) is preferentially recommended for American Indian and Alaska Native (AI/AN) infants
  - It provides a protective antibody response after the first dose
  - Historically, Hib meningitis peaked at an earlier age among AI/AN infants
- Vaxelis (DTaP-IPV-Hib-HepB) does not currently have a preferential recommendation for AI/AN infants because
  - It contains PRP-OMP in a lower amount than PedvaxHIB
  - Post-dose 1 immunogenicity data were not previously available

# Policy question

Should DTaP-IPV-Hib-HepB (Vaxelis) be included with PRP-OMP (PedvaxHIB) in the preferential recommendation for American Indian and Alaska Native (AI/AN) infants based on the Hib component?

# February 2024 ACIP Meeting Presentations

- Epidemiology of invasive Hib disease in AI/AN populations and evidence supporting the existing preferential recommendation for PedvaxHIB
- Clinical trial data on post-dose 1 immunogenicity of Vaxelis vs. PedvaxHIB
- Preliminary Work Group considerations

# Today's agenda

Topic	Presenter
Evidence to Recommendations and Proposed Recommendations: Use of Vaxelis among American Indian and Alaska Native Infants	Dr. Jennifer Collins (CDC/NCIRD)
Updated Vaccines for Children (VFC) Resolution	Dr. Jeanne Santoli (CDC/NCIRD)

**All topics will be presented for information, discussion, and vote**